{"denoms":[{"counts":[{"groupId":"BG000","value":"599"},{"groupId":"BG001","value":"599"},{"groupId":"BG002","value":"1198"}],"units":"Participants"}],"groups":[{"description":"Cetuximab intravenous infusion of 400mg/m\\^2 for the first infusion then weekly intravenous infusion of 250mg/m\\^2. Bi-weekly Irinotecan infusion of 180mg/m\\^2, Folinic Acid infusion of 400mg/m\\^2 (racemic) or 200mg/m\\^2 (L-form), 5-Fluorouracil bolus of 400mg/m\\^2 followed by a 46-hour continuous infusion of 2400mg/m\\^2 Number of Cycles: until progression or unacceptable toxicity develops","id":"BG000","title":"Cetuximab Plus FOLFIRI"},{"description":"Bi-weekly Irinotecan infusion of 180mg/m\\^2, Folinic Acid infusion of 400mg/m\\^2 (racemic) or 200mg/m\\^2 (L-form), 5-Fluorouracil bolus of 400mg/m\\^2 followed by a 46-hour continuous infusion of 2400mg/m\\^2 Number of Cycles: until progression or unacceptable toxicity develops","id":"BG001","title":"FOLFIRI Alone"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.52","value":"60.0"},{"groupId":"BG001","spread":"11.06","value":"59.8"},{"groupId":"BG002","spread":"10.79","value":"59.9"}]}]}],"description":"Age missing for 1 subject","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}],"title":"Missing"},{"categories":[{"measurements":[{"groupId":"BG000","value":"374"},{"groupId":"BG001","value":"377"},{"groupId":"BG002","value":"751"}]}],"title":"Between 18 and 65 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"224"},{"groupId":"BG001","value":"222"},{"groupId":"BG002","value":"446"}]}],"title":">=65 years"}],"description":"Age missing for 1 subject","paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"230"},{"groupId":"BG001","value":"243"},{"groupId":"BG002","value":"473"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"369"},{"groupId":"BG001","value":"356"},{"groupId":"BG002","value":"725"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Gender","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"262"},{"groupId":"BG001","value":"267"},{"groupId":"BG002","value":"529"}]}],"title":"Western Europe"},{"categories":[{"measurements":[{"groupId":"BG000","value":"203"},{"groupId":"BG001","value":"201"},{"groupId":"BG002","value":"404"}]}],"title":"Eastern Europe"},{"categories":[{"measurements":[{"groupId":"BG000","value":"134"},{"groupId":"BG001","value":"131"},{"groupId":"BG002","value":"265"}]}],"title":"Rest of the World"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}